This clinical trial is focused on studying a condition called Polymyalgia Rheumatica (PMR), which is a disorder that causes muscle pain and stiffness, especially in the shoulders. The study is testing a treatment using a medication called Secukinumab, also known by its code name AIN457. Secukinumab is given as an injection under the skin. The trial also involves a medication called Prednisone, which is a type of glucocorticoid, a drug that helps reduce inflammation and suppress the immune system. Participants in the study will receive either Secukinumab or a placebo, along with a tapering dose of Prednisone over a period of 24 weeks.

The purpose of the study is to determine if Secukinumab, when combined with a glucocorticoid taper regimen, is more effective than a placebo in helping patients with PMR achieve sustained remission, which means the symptoms of the disease are reduced or disappear for a period of time. The study will last for up to 52 weeks, during which participants will be monitored to see how well they respond to the treatment. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will have regular check-ups to assess their health and the effectiveness of the treatment. The main goal is to see how many participants achieve sustained remission by the end of the study. Additionally, the study will look at the overall safety and tolerability of the treatment, including any side effects that may occur. This research aims to provide valuable information on the potential benefits of Secukinumab for people with Polymyalgia Rheumatica.